Inspire Medical Systems has reported a significant 84% rise in Q1 2023 revenue, reaching $127.9 million, driven by its innovative treatments for Obstructive Sleep Apnea. The company has received FDA ...

Detailed price information for Inspire Medical Systems Inc (INSP-N) from The Globe and Mail including charting and trades.

MINNEAPOLIS, July 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, ...

MINNEAPOLIS, June 16, 2020 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and ...

Revenue for full year 2025 is anticipated to be in the range of $940 million to $955 million, a 17% to 19% increase over full year 2024 “We are very pleased with our strong preliminary revenue ...

The Food and Drug Administration (FDA) has expanded the approval of Inspire therapy (Inspire Medical Systems) to include patients aged 18 to 21 years with moderate to severe obstructive sleep apnea ...

MINNEAPOLIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, ...

Over 22 million Americans suffer from sleep apnea. The causes and intensity of symptoms of sleep apnea vary person to person, so it's important to be aware of the treatment options available.

DETROIT, June 5, 2025 /PRNewswire/ -- Inspire Autism, a growing provider of evidence-based therapy for children diagnosed with autism spectrum disorder, announces the appointment of Kristin M. Hustyi, ...